Dr. Nicholas Carman was born in Brisbane, Australia where he undertook his medical training at the University of Queensland. He completed his pediatric training and subsequent Gastroenterology fellowship at the Royal Children’s Hospital in Brisbane in 2014. Following this he moved to Canada and completed an Inflammatory Bowel Disease Fellowship at the Hospital for Sick Children in Toronto, where he has also worked as a locum Staff Gastroenterologist since 2016.
In 2017, he joined the University of Ottawa as an Assistant Professor in the Department of Pediatrics in Pediatric Gastroenterology at the Children’s Hospital of Eastern Ontario (CHEO). His research interests are in endoscopic measurement tools and clinical Inflammatory Bowel Disease.
Vedolizumab Therapy in Children With Primary Sclerosing Cholangitis
Liver biochemistry worsened over time in IBD unresponsive to VDZ, but remained unchanged in IBD patients in remission. VDZ did not improve liver biochemistry in pediatric PSC-IBD. Progressive liver disease may be more common in patients with medically-refractory IBD.
Clinical disease activity and endoscopic severity correlate poorly in children newly diagnosed with Crohn’s disease
In children with newly diagnosed CD, wPCDAI correlates poorly with endoscopic disease activity. As treatment paradigms evolve to target mucosal healing, clinical markers should not be used in isolation to determine disease activity.
Symptoms do not correlate with findings from colonoscopy in children with inflammatory bowel disease and primary sclerosing cholangitis
Children with PSC-IBD in clinical remission, based on PUCAI scores, have a significantly higher risk of active endoscopic and histologic disease than children with colitis without PSC. Fecal levels of calprotectin correlate with endoscopic findings in pediatric patients with PSC-IBD; levels below 93 μg/g are associated with mucosal healing.